TAK-771

Phase 3Small molecule

TAK-771 is one of 25 small molecule programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyActive, not recruiting

Immunodeficiency DiseaseActive, not recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 3

Active, not recruiting

Immunodeficiency DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Immunodeficiency Disease

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

—2

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—3

Epivir

GGlaxo Dba Glaxosmithkline

Retrovir

Asceniv

1 6

HYQVIA

Takeda

Phase 3

1 7

TAK-881

Takeda

Phase 3

3 8

Newgam

Octapharma

Phase 3

1 9

TAK-771

Takeda

Phase 3

2 10

Octanorm

Octapharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency Disease2 trials

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Completed· Takeda logo

Takeda·Phase 3·NCT05513586·15 enrolled

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Completed· Takeda logo

Takeda·Phase 3·NCT05150340·16 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese Subjects

Completed· Takeda logo

Takeda·Phase 3·NCT05084053·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TAK-771. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-771 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-771. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-771

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency Disease2 trials

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

References

Drug Info

Quick Facts

Related News